Literature DB >> 21607291

A nonerythropoietic peptide that mimics the 3D structure of erythropoietin reduces organ injury/dysfunction and inflammation in experimental hemorrhagic shock.

Nimesh S A Patel1, Kiran K Nandra, Michael Brines, Massimo Collino, Ws Fred Wong, Amar Kapoor, Elisa Benetti, Fera Y Goh, Roberto Fantozzi, Anthony Cerami, Christoph Thiemermann.   

Abstract

Recent studies have shown that erythropoietin, critical for the differentiation and survival of erythrocytes, has cytoprotective effects in a wide variety of tissues, including the kidney and lung. However, erythropoietin has been shown to have a serious side effect-an increase in thrombovascular effects. We investigated whether pyroglutamate helix B-surface peptide (pHBSP), a nonerythropoietic tissue-protective peptide mimicking the 3D structure of erythropoietin, protects against the organ injury/ dysfunction and inflammation in rats subjected to severe hemorrhagic shock (HS). Mean arterial blood pressure was reduced to 35 ± 5 mmHg for 90 min followed by resuscitation with 20 mL/kg Ringer Lactate for 10 min and 50% of the shed blood for 50 min. Rats were euthanized 4 h after the onset of resuscitation. pHBSP was administered 30 min or 60 min into resuscitation. HS resulted in significant organ injury/dysfunction (renal, hepatic, pancreas, neuromuscular, lung) and inflammation (lung). In rats subjected to HS, pHBSP significantly attenuated (i) organ injury/dysfunction (renal, hepatic, pancreas, neuromuscular, lung) and inflammation (lung), (ii) increased the phosphorylation of Akt, glycogen synthase kinase-3β and endothelial nitric oxide synthase, (iii) attenuated the activation of nuclear factor (NF)-κB and (iv) attenuated the increase in p38 and extracellular signal-regulated kinase (ERK)1/2 phosphorylation. pHBSP protects against multiple organ injury/dysfunction and inflammation caused by severe hemorrhagic shock by a mechanism that may involve activation of Akt and endothelial nitric oxide synthase, and inhibition of glycogen synthase kinase-3β and NF-κB.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21607291      PMCID: PMC3188881          DOI: 10.2119/molmed.2011.00053

Source DB:  PubMed          Journal:  Mol Med        ISSN: 1076-1551            Impact factor:   6.354


  54 in total

Review 1.  The IKK/NF-kappa B pathway.

Authors:  Uwe Senftleben; Michael Karin
Journal:  Crit Care Med       Date:  2002-01       Impact factor: 7.598

2.  Requirement for glycogen synthase kinase-3beta in cell survival and NF-kappaB activation.

Authors:  K P Hoeflich; J Luo; E A Rubie; M S Tsao; O Jin; J R Woodgett
Journal:  Nature       Date:  2000-07-06       Impact factor: 49.962

3.  Genetic deletion of glycogen synthase kinase-3beta abrogates activation of IkappaBalpha kinase, JNK, Akt, and p44/p42 MAPK but potentiates apoptosis induced by tumor necrosis factor.

Authors:  Yasunari Takada; Xianjun Fang; Md Saha Jamaluddin; Douglas D Boyd; Bharat B Aggarwal
Journal:  J Biol Chem       Date:  2004-07-13       Impact factor: 5.157

4.  Erythropoietin attenuates the tissue injury associated with hemorrhagic shock and myocardial ischemia.

Authors:  Maha Abdelrahman; Edward J Sharples; Michelle C McDonald; Marika Collin; Nimesh S A Patel; Muhammad M Yaqoob; Christoph Thiemermann
Journal:  Shock       Date:  2004-07       Impact factor: 3.454

5.  Erythropoietin protects the kidney against the injury and dysfunction caused by ischemia-reperfusion.

Authors:  Edward J Sharples; Nimesh Patel; Paul Brown; Keith Stewart; Helder Mota-Philipe; Michael Sheaff; Julius Kieswich; David Allen; Steven Harwood; Martin Raftery; Christoph Thiemermann; Muhammad M Yaqoob
Journal:  J Am Soc Nephrol       Date:  2004-08       Impact factor: 10.121

6.  Seven hundred fifty-three consecutive deaths in a level I trauma center: the argument for injury prevention.

Authors:  Ronald M Stewart; John G Myers; Daniel L Dent; Peter Ermis; Gina A Gray; Roberto Villarreal; Osbert Blow; Brian Woods; Marilyn McFarland; Jan Garavaglia; Harlan D Root; Basil A Pruitt
Journal:  J Trauma       Date:  2003-01

7.  A novel, potent and selective inhibitor of the activity of inducible nitric oxide synthase (GW274150) reduces the organ injury in hemorrhagic shock.

Authors:  M C McDonald; M Izumi; S Cuzzocrea; C Thiemermann
Journal:  J Physiol Pharmacol       Date:  2002-12       Impact factor: 3.011

8.  Defining the involvement of p38alpha MAPK in the production of anti- and proinflammatory cytokines using an SB 203580-resistant form of the kinase.

Authors:  Xuecui Guo; Robert E Gerl; John W Schrader
Journal:  J Biol Chem       Date:  2003-03-11       Impact factor: 5.157

9.  Role of glycogen synthase kinase-3 in TNF-alpha-induced NF-kappaB activation and apoptosis in hepatocytes.

Authors:  Robert F Schwabe; David A Brenner
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2002-07       Impact factor: 4.052

10.  The attenuation of hemorrhage-induced liver injury by exogenous nitric oxide, L-arginine, and inhibition of inducible nitric oxide synthase.

Authors:  Roberto Anaya-Prado; Luis H Toledo-Pereyra; R F Guo; J Reuben; Peter A Ward; J Walsh
Journal:  J Invest Surg       Date:  2003 Sep-Oct       Impact factor: 2.533

View more
  14 in total

Review 1.  The receptor that tames the innate immune response.

Authors:  Michael Brines; Anthony Cerami
Journal:  Mol Med       Date:  2012-05-09       Impact factor: 6.354

2.  The Protective Effects of Helix B Surface Peptide on Experimental Acute Liver Injury Induced by Carbon Tetrachloride.

Authors:  Shengdi Wu; Cheng Yang; Nuo Xu; Lingyan Wang; Yun Liu; Jiyao Wang; Xizhong Shen
Journal:  Dig Dis Sci       Date:  2017-04-01       Impact factor: 3.199

3.  Inhibition of IκB Kinase Attenuates the Organ Injury and Dysfunction Associated with Hemorrhagic Shock.

Authors:  Regina Sordi; Fausto Chiazza; Florence L Johnson; Nimesh S A Patel; Karim Brohi; Massimo Collino; Christoph Thiemermann
Journal:  Mol Med       Date:  2015-06-18       Impact factor: 6.354

4.  Treatment of mild traumatic brain injury with an erythropoietin-mimetic peptide.

Authors:  Claudia S Robertson; Robert Garcia; Samson Sujit Kumar Gaddam; Raymond J Grill; Carla Cerami Hand; Tian Siva Tian; H Julia Hannay
Journal:  J Neurotrauma       Date:  2012-09-20       Impact factor: 5.269

5.  ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes.

Authors:  Michael Brines; Ann N Dunne; Monique van Velzen; Paolo L Proto; Claes-Goran Ostenson; Rita I Kirk; Ioannis N Petropoulos; Saad Javed; Rayaz A Malik; Anthony Cerami; Albert Dahan
Journal:  Mol Med       Date:  2015-03-13       Impact factor: 6.354

6.  Delayed administration of pyroglutamate helix B surface peptide (pHBSP), a novel nonerythropoietic analog of erythropoietin, attenuates acute kidney injury.

Authors:  Nimesh S A Patel; Hannah L Kerr-Peterson; Michael Brines; Massimo Collino; Mara Rogazzo; Roberto Fantozzi; Elizabeth G Wood; Florence L Johnson; Muhammad M Yaqoob; Anthony Cerami; Christoph Thiemermann
Journal:  Mol Med       Date:  2012-05-09       Impact factor: 6.354

7.  Alternative erythropoietin-mediated signaling prevents secondary microvascular thrombosis and inflammation within cutaneous burns.

Authors:  Stefan Bohr; Suraj J Patel; Keyue Shen; Antonia G Vitalo; Michael Brines; Anthony Cerami; Francois Berthiaume; Martin L Yarmush
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-11       Impact factor: 11.205

8.  Pharmacological preconditioning with erythropoietin attenuates the organ injury and dysfunction induced in a rat model of hemorrhagic shock.

Authors:  Kiran K Nandra; Massimo Collino; Mara Rogazzo; Roberto Fantozzi; Nimesh S A Patel; Christoph Thiemermann
Journal:  Dis Model Mech       Date:  2012-12-20       Impact factor: 5.758

9.  ARA290, a non-erythropoietic EPO derivative, attenuates renal ischemia/reperfusion injury.

Authors:  Willem G van Rijt; Gertrude J Nieuwenhuijs-Moeke; Harry van Goor; Bente Jespersen; Petra J Ottens; Rutger J Ploeg; Henri G D Leuvenink
Journal:  J Transl Med       Date:  2013-01-09       Impact factor: 5.531

Review 10.  Erythropoietin Receptor/β Common Receptor: A Shining Light on Acute Kidney Injury Induced by Ischemia-Reperfusion.

Authors:  Yuanyuan Wu; Bin Yang
Journal:  Front Immunol       Date:  2021-06-30       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.